Skip to content

PharmaMar Orphan Drug Lurbinectedin’s Ovarian Cancer Trial Results At ESMO 2012 (September 30, 2012)

September 30, 2012

        On September 30, 2012, PharmaMar’s orphan drug Lurbinectedin’s Phase II clinical trial results is presented at the 37th European Society for Medical Oncology (ESMO).  ESMO is being held in Vienna, Austria, September 28 – October 2, 2012. 

        By going to the “Search ESMO 2012 page” & entering Lurbinectedin into the search box, the following September 30, 2012 Abstract presentation can be found :

     [3:30 PM] 968O | Lurbinectedin (PM01183) activity in platinum-resistant/refractory ovarian cancer patients. Preliminary results of an ongoing two-stage Phase II study.

         Just to recap the approval history of Lurbinectedin :

1) On August 20, 2012, PharmaMar receives FDA Orphan Drug Designation (ODD) for Lurbinectedin (PM01183) for the treatment of ovarian cancer

2)  This is followed by EMA COMP’s positive opinion in early September 2012 for orphan drug status for the treatment of ovarian cancer. 

References

ESMO 2012 September 30, 2012 Press Release titled,”Lurbinectedin shows activity in patients with platinum-resistant/refractory ovarian cancer”.

Copyright © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: